A Phase III, Randomized, Double-Blind Study of Tiragolumab Plus Atezolizumab Compared with Placebo Plus Atezolizumab in Participants with Completely Resected Stage IIB, IIIA, or Select IIIB, PD-L1 Positive, Non-Small Cell Lung Cancer who have received Adjuvant Platinum-Based Chemotherapy

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506696-10-00

Acronym

GO45006

Enrollment

576

Registered

2024-05-21

Start date

2024-06-18

Completion date

2025-11-17

Last updated

2025-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Small Cell Lung Cancer

Brief summary

1. Incidence and severity of adverse events, with severity determined according to NCI CTCAE v5.0

Interventions

None listed

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
1. Incidence and severity of adverse events, with severity determined according to NCI CTCAE v5.0	—

Countries

Austria, Belgium, France, Germany, Greece, Hungary, Ireland, Italy, Poland, Romania, Slovakia, Spain

Outcome results